文献速递临床试验与 GCP基础与转化研究

动脉内选择性低温治疗急性缺血性卒中神经保护:中国多中心先导试验

Intra-arterial selective hypothermia for acute ischemic stroke neuroprotection: A multicenter pilot trial in China.
PubMed 文献 · PLoS Med · 2025-07-24

在中国18家卒中中心纳入100例前循环大血管闭塞的急性缺血性卒中患者,随机分为动脉内局部治疗性低温联合标准治疗组与单纯标准治疗组。90天良好功能结局在低温组为58.0%(29/50)vs 对照组40.0%(20/50),aRR 1.47(95% CI [0.99, 2.16];P=0.055),未达统计学显著。症状性颅内出血和死亡率组间无显著差异。

要点

  • 动脉内局部治疗性低温联合血管内治疗90天良好功能结局58.0% vs 40.0%,aRR 1.47(95% CI [0.99, 2.16];P=0.055),未达统计学显著。
  • 症状性颅内出血8.0%(4/50)vs 16.0%(8/50),死亡率20.0%(10/50)vs 22.0%(11/50),组间无显著差异。
  • 作者认为该先导研究提示动脉内局部治疗性低温可能可行且安全,但主要结局未达统计学显著,需在更大规模试验中进一步研究。

核心结论

  • 该先导研究提供初步见解,提示动脉内局部治疗性低温联合血管内治疗可能可行且安全,并可能改善急性缺血性卒中患者的功能结局。
  • 主要结局未达统计学显著,但观察到的数值差异提示动脉内局部治疗性低温值得在更大规模试验中进一步研究。

研究设计与样本

  • 多中心、随机、结局评估盲法的先导试验(ISOLATION试验),结局评估者和患者对治疗分配设盲,操作人员无法设盲,注册号ChiCTR2300074990。
  • 2023年9月至2024年1月从中国18家卒中中心招募100例卒中发作24小时内的前循环大血管闭塞患者。
  • 参与者按1:1随机分配至动脉内局部治疗性低温联合标准治疗组(干预组,n=50)或单纯标准治疗组(对照组,n=50)。
  • 干预组在血管内治疗期间及之后接受4°C生理盐水动脉内输注。
  • 主要结局为90天良好功能结局(改良Rankin量表0-2分)。

主要发现

  • 在意向性治疗分析中,参与者中位年龄69岁,男性64%(64/100),美国国立卫生研究院卒中量表评分中位数14分。
  • 90天良好功能结局在动脉内局部治疗性低温组为58.0%(29/50)vs 对照组40.0%(20/50),aRR 1.47(95% CI [0.99, 2.16];P=0.055),未达统计学显著。
  • 症状性颅内出血发生率动脉内局部治疗性低温组8.0%(4/50)vs 对照组16.0%(8/50),组间无显著差异。
  • 死亡率动脉内局部治疗性低温组20.0%(10/50)vs 对照组22.0%(11/50),组间无显著差异。

临床怎么用

  • 作者认为动脉内局部治疗性低温联合血管内治疗可能可行且安全,并可能改善急性缺血性卒中患者的功能结局。
  • 作者指出主要结局未达统计学显著,观察到的数值差异提示动脉内局部治疗性低温值得在更大规模试验中进一步研究。

局限性

  • 该先导研究样本量不足,限制了检测主要结局差异的统计效能。
  • 由于样本量小,无法校正年龄和ASPECTS之外的其他潜在重要混杂因素。
  • 动脉内局部治疗性低温组肺部感染发生率较高,可能由低温诱导的免疫抑制或镇静相关因素所致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute ischemic stroke (AIS) remains a leading cause of disability and death globally, with limited effective neuroprotective strategies beyond reperfusion therapies. Despite advances in reperfusion treatments, many patients still experience poor outcomes, highlighting the urgent need for additional therapeutic approaches. We investigated whether intra-arterial local therapeutic hypothermia (IA-LTH) combined with endovascular treatment could improve outcomes in patients with AIS. METHODS AND FINDINGS: We conducted a multicenter, randomized trial with blinded outcome assessment (ISOLATION trial), where outcome assessors and patients were blinded to treatment allocation while procedural staff could not be blinded, to test the effectiveness of IA-LTH for neuroprotection in AIS (registration number: ChiCTR2300074990). Between September 2023 and January 2024, we recruited 100 patients with anterior circulation large vessel occlusion within 24 h of stroke onset from 18 stroke centers in China. Participants were randomly assigned (1:1) to receive either IA-LTH plus standard care (including endovascular treatment and guideline-recommended medical therapy; intervention; n = 50) or standard care alone (control; n = 50). The IA-LTH group received intra-arterial infusion of 4 °C saline during and following endovascular treatment. Primary outcome was favorable functional outcome (modified Rankin Scale 0-2) at 90 days. Using intention-to-treat analysis, among participants (median age 69 years, 64% [64/100] male, median National Institutes of Health Stroke Scale score 14), the primary outcome did not reach statistical significance, with favorable outcome achieved in 58.0% (29/50) of the IA-LTH group versus 40.0% (20/50) of controls (adjusted relative risk [aRR] of 1.47 (95% CI [0.99, 2.16]; P = 0.055)). This lack of statistical significance is primarily due to the limited sample size of this pilot study, which was designed to assess feasibility and safety rather than provide definitive efficacy evidence. Safety outcomes, including rates of symptomatic intracranial hemorrhage (8.0% [4/50] versus 16.0% [8/50]) and mortality (20.0% [10/50] versus 22.0% [11/50]), were not significantly different between groups. The main limitations include the insufficient sample size of this pilot study which limited statistical power to detect differences in the primary outcome, the inability to adjust for potentially important confounders beyond age and ASPECTS due to the small sample size, and the higher incidence of pulmonary infections in the IA-LTH group that may have resulted from hypothermia-induced immune suppression or sedation-related factors. CONCLUSIONS: This pilot study provides preliminary insights suggesting that IA-LTH combined with endovascular therapy may be feasible and safe, with potential to improve functional outcomes in patients with AIS. The primary outcome did not reach statistical significance. However, the observed numerical differences suggest that IA-LTH warrants further investigation in larger trials. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR) ChiCTR2300074990.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Huang ZX, Hu M, Zhang P, et al. Intra-arterial selective hypothermia for acute ischemic stroke neuroprotection: A multicenter pilot trial in China. PLoS Med. 2025. PMID: 40705740. doi:10.1371/journal.pmed.1004668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。